Renal Cell Carcinoma (2024)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249. [PubMed] [Google Scholar]

2. Russo P. Contemporary understanding and management of renal cortical tumors. Urol Clin North Am. 2008;35:xiii–xvii. [PubMed] [Google Scholar]

3. Decastro GJ, McKiernan JM. Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin North Am. 2008;35:581–592. vi. [PubMed] [Google Scholar]

4. Dhote R, Pellicer-Coeuret M, Thiounn N, Debre B, Vidal-Trecan G. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int. 2000;86:20–27. [PubMed] [Google Scholar]

5. Gibbons RP, Monte JE, Correa RJ, Jr, Mason JT. Manifestations of renal cell carcinoma. Urology. 1976;8:201–206. [PubMed] [Google Scholar]

6. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–2490. [PubMed] [Google Scholar]

7. Jones PA, Vogelzang NJ, Gomez Jao. Report of the Kidney/Bladder Cancer Progress Review Group. NCI. 2002 [Google Scholar]

8. Hutson TE, Figlin RA. Novel therapeutics for metastatic renal cell carcinoma. Cancer. 2009;115:2361–2367. [PubMed] [Google Scholar]

9. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131–133. [PubMed] [Google Scholar]

10. American Joint Committee on Cancer. AJCC Cancer Staging Handbook. 7. Springer; 2010. [Google Scholar]

11. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol. 2002;167:57–60. [PubMed] [Google Scholar]

12. Delahunt B, Bethwaite PB, Nacey JN. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology. 2007;39:459–465. [PubMed] [Google Scholar]

13. Delahunt B. Advances and controversies in grading and staging of renal cell carcinoma. Mod Pathol. 2009;22(Suppl 2):S24–36. [PubMed] [Google Scholar]

14. Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer. 2004;4:381–393. [PubMed] [Google Scholar]

15. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260:1317–1320. [PubMed] [Google Scholar]

16. Pavlovich CP, Schmidt LS, Phillips JL. The genetic basis of renal cell carcinoma. Urol Clin North Am. 2003;30:437–454. vii. [PubMed] [Google Scholar]

17. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 1994;7:85–90. [PubMed] [Google Scholar]

18. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010 [PMC free article] [PubMed] [Google Scholar]

19. Dulaimi E, Ibanez De Caceres I, Uzzo RG, et al. Promoter Hypermethylation Profile of Kidney Cancer. Clinical Cancer Research. 2004 [PubMed] [Google Scholar]

20. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008;14:435–446. [PMC free article] [PubMed] [Google Scholar]

21. Kaelin WG., Jr The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007;13:680s–684s. [PubMed] [Google Scholar]

22. Linehan WM, Zbar B. Focus on kidney cancer. Cancer Cell. 2004;6:223–228. [PubMed] [Google Scholar]

23. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–351. [PubMed] [Google Scholar]

24. Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009;69:4674–4681. [PMC free article] [PubMed] [Google Scholar]

25. Moch H, Sauter G, Gasser TC, et al. EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization. J Pathol. 1998;184:424–429. [PubMed] [Google Scholar]

26. Moch H, Sauter G, Buchholz N, et al. Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol. 1997;28:1255–1259. [PubMed] [Google Scholar]

27. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 1999;5:1966–1975. [PubMed] [Google Scholar]

28. Weidner U, Peter S, Strohmeyer T, Hussnatter R, Ackermann R, Sies H. Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma. Cancer Res. 1990;50:4504–4509. [PubMed] [Google Scholar]

29. Kovacs G, Szucs S, De Riese W, Baumgartel H. Specific chromosome aberration in human renal cell carcinoma. Int J Cancer. 1987;40:171–178. [PubMed] [Google Scholar]

30. Thrash-Bingham CA, Greenberg RE, Howard S, et al. Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes. Proc Natl Acad Sci USA. 1995;92:2854–2858. [PMC free article] [PubMed] [Google Scholar]

31. Wilhelm M, Veltman JA, Olshen AB, et al. Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res. 2002;62:957–960. [PubMed] [Google Scholar]

32. Cairns P, Polascik TJ, Eby Y, et al. Frequency of hom*ozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet. 1995;11:210–212. [PubMed] [Google Scholar]

33. Haibach H, Burns TW, Carlson HE, Burman KD, Deftos LJ. Multiple hamartoma syndrome (Cowden’s disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma) Am J Clin Pathol. 1992;97:705–712. [PubMed] [Google Scholar]

34. Cairns P, Evron E, Okami K, et al. Point mutation and hom*ozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene. 1998;16:3215–3218. [PubMed] [Google Scholar]

35. Zysman MA, Chapman WB, Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol. 2002;160:795–800. [PMC free article] [PubMed] [Google Scholar]

36. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12:417–423. [PubMed] [Google Scholar]

37. Kovacs G, Emanuel A, Neumann HP, Kung HF. Cytogenetics of renal cell carcinomas associated with von Hippel-Lindau disease. Genes Chromosomes Cancer. 1991;3:256–262. [PubMed] [Google Scholar]

38. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A. 2001;98:9754–9759. [PMC free article] [PubMed] [Google Scholar]

39. Vasselli JR, Shih JH, Iyengar SR, et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A. 2003;100:6958–6963. [PMC free article] [PubMed] [Google Scholar]

40. Jones J, Otu H, Spentzos D, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005;11:5730–5739. [PubMed] [Google Scholar]

41. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol. 2003;162:925–932. [PMC free article] [PubMed] [Google Scholar]

42. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene. 2003;22:6810–6818. [PubMed] [Google Scholar]

43. Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001;158:1639–1651. [PMC free article] [PubMed] [Google Scholar]

44. Rohan S, Tu JJ, Kao J, et al. Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clinical Cancer Research. 2006;12:6937–6945. [PubMed] [Google Scholar]

45. Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005;65:5628–5637. [PubMed] [Google Scholar]

46. Abdulrahman M, Maina EN, Morris MR, et al. Identification of novel VHL targets that are associated with the development of renal cell carcinoma. Oncogene. 2007;26:1661–1672. [PubMed] [Google Scholar]

47. Maina EN, Morris MR, Zatyka M, et al. Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene. 2005;24:4549–4558. [PubMed] [Google Scholar]

48. Furge KA, Tan MH, Dykema K, et al. Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling. Oncogene. 2007;26:1346–1350. [PubMed] [Google Scholar]

49. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 2008;22:3696–3705. [PubMed] [Google Scholar]

50. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res. 2006;66:5021–5028. [PubMed] [Google Scholar]

51. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA. 1994;91:9700–9704. [PMC free article] [PubMed] [Google Scholar]

52. da Silva NF, Gentle D, Hesson LB, Morton DG, Latif F, Maher ER. Analysis of the Birt-Hogg-Dube (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. J Med Genet. 2003;40:820–824. [PMC free article] [PubMed] [Google Scholar]

53. Gad S, Lefevre SH, Khoo SK, et al. Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer. 2007;96:336–340. [PMC free article] [PubMed] [Google Scholar]

54. Esteller M, Sparks A, Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res. 2000;60:4366–4371. [PubMed] [Google Scholar]

55. Dahl E, Wiesmann F, Woenckhaus M, et al. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene. 2007;26:5680–5691. [PubMed] [Google Scholar]

56. Urakami S, Shiina H, Enokida H, et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin Cancer Res. 2006;12:2109–2116. [PubMed] [Google Scholar]

58. Jung M, Mollenkopf HJ, Grimm C, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med. 2009;13:3918–3928. [PMC free article] [PubMed] [Google Scholar]

59. Nakada C, Matsuura K, Tsukamoto Y, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol. 2008;216:418–427. [PubMed] [Google Scholar]

60. Juan D, Alexe G, Antes T, et al. Identification of a MicroRNA Panel for Clear-cell Kidney Cancer. Urology. 2009 [PubMed] [Google Scholar]

61. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16:68–73. [PubMed] [Google Scholar]

62. Zhuang Z, Park WS, Pack S, et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet. 1998;20:66–69. [PubMed] [Google Scholar]

63. Fischer J, Palmedo G, von Knobloch R, et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene. 1998;17:733–739. [PubMed] [Google Scholar]

64. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18:2343–2350. [PubMed] [Google Scholar]

65. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10:537–544. [PubMed] [Google Scholar]

66. Szponar A, Zubakov D, Pawlak J, Jauch A, Kovacs G. Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression. Int J Cancer. 2009;124:2071–2076. [PubMed] [Google Scholar]

67. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32:590–595. [PubMed] [Google Scholar]

68. Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155:517–526. [PMC free article] [PubMed] [Google Scholar]

69. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406–410. [PubMed] [Google Scholar]

70. Kiuru M, Lehtonen R, Arola J, et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res. 2002;62:4554–4557. [PubMed] [Google Scholar]

71. Kovacs G, Fuzesi L, Emanual A, Kung HF. Cytogenetics of papillary renal cell tumors. Genes Chromosomes Cancer. 1991;3:249–255. [PubMed] [Google Scholar]

72. Kovacs G. Molecular cytogenetics of renal cell tumors. Adv Cancer Res. 1993;62:89–124. [PubMed] [Google Scholar]

73. Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res. 1995;55:224–227. [PubMed] [Google Scholar]

74. Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol. 1997;183:151–155. [PubMed] [Google Scholar]

75. Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994;145:356–364. [PMC free article] [PubMed] [Google Scholar]

76. Bugert P, Kovacs G. Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol. 1996;149:2081–2088. [PMC free article] [PubMed] [Google Scholar]

77. Kenck C, Wilhelm M, Bugert P, Staehler G, Kovacs G. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol. 1996;179:157–161. [PubMed] [Google Scholar]

78. Contractor H, Zariwala M, Bugert P, Zeisler J, Kovacs G. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J Pathol. 1997;181:136–139. [PubMed] [Google Scholar]

79. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene. 2003;22:847–852. [PubMed] [Google Scholar]

80. Haitel A, Susani M, Wick N, Mazal PR, Wrba F. c-kit overexpression in chromophobe renal cell carcinoma is not associated with c-kit mutation of exons 9 and 11. Am J Surg Pathol. 2005;29:842. [PubMed] [Google Scholar]

81. Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008;45:321–331. [PMC free article] [PubMed] [Google Scholar]

82. Nickerson ML, Warren MB, Toro JR, et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell. 2002;2:157–164. [PubMed] [Google Scholar]

83. Khoo SK, Kahnoski K, Sugimura J, et al. Inactivation of BHD in sporadic renal tumors. Cancer Res. 2003;63:4583–4587. [PubMed] [Google Scholar]

84. Nagy A, Zoubakov D, Stupar Z, Kovacs G. Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma. Int J Cancer. 2004;109:472–475. [PubMed] [Google Scholar]

85. Polascik TJ, Cairns P, Epstein JI, et al. Distal nephron renal tumors: microsatellite allelotype. Cancer Res. 1996;56:1892–1895. [PubMed] [Google Scholar]

86. Steiner G, Cairns P, Polascik TJ, et al. High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1–32.2. Cancer Res. 1996;56:5044–5046. [PubMed] [Google Scholar]

87. Schoenberg M, Cairns P, Brooks JD, et al. Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. Genes Chromosomes Cancer. 1995;12:76–80. [PubMed] [Google Scholar]

88. Srigley JR, Delahunt B. Uncommon and recently described renal carcinomas. Mod Pathol. 2009;22(Suppl 2):S2–S23. [PubMed] [Google Scholar]

89. Presti J, Moch JCH, Gelb AB, Huynh D, Waldman FM. Initiating genetic events in small renal neoplasms detected by comparative genomic hybridization. J Urol. 1998;160:1557–1561. [PubMed] [Google Scholar]

90. Van Poppel H, Nilsson S, Algaba F, et al. Precancerous lesions in the kidney. Scand J Urol Nephrol Suppl. 2000:136–165. [PubMed] [Google Scholar]

91. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol. 1996;149:2089–2094. [PMC free article] [PubMed] [Google Scholar]

92. Junker K, Thrum K, Schlichter A, Muller G, Hindermann W, Schubert J. Clonal origin of multifocal renal cell carcinoma as determined by microsatellite analysis. J Urol. 2002;168:2632–2636. [PubMed] [Google Scholar]

93. Miyake H, Nakamura H, Hara I, et al. Multifocal renal cell carcinoma: evidence for a common clonal origin. Clin Cancer Res. 1998;4:2491–2494. [PubMed] [Google Scholar]

94. Cheng L, MacLennan GT, Zhang S, et al. Evidence for polyclonal origin of multifocal clear cell renal cell carcinoma. Clin Cancer Res. 2008;14:8087–8093. [PubMed] [Google Scholar]

95. Jones TD, Eble JN, Wang M, et al. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res. 2005;11:7226–7233. [PubMed] [Google Scholar]

96. Kovacs G. Re: clonal origin of multifocal renal cell carcinoma as determined by microsatellite analysis. J Urol. 2003;170:1325–1326. author reply 1326. [PubMed] [Google Scholar]

97. Jang SJ, Mao L. Methylation patterns in human androgen receptor gene and clonality analysis. Cancer Res. 2000;60:864–866. [PubMed] [Google Scholar]

98. Gohji K, Hara I, Gotoh A, et al. Multifocal renal cell carcinoma in Japanese patients with tumors with maximal diameters of 50 mm. or less. J Urol. 1998;159:1144–1147. [PubMed] [Google Scholar]

99. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–1279. [PubMed] [Google Scholar]

100. Reuter VE, Presti JC., Jr Contemporary approach to the classification of renal epithelial tumors. Semin Oncol. 2000;27:124–137. [PubMed] [Google Scholar]

101. Wiklund F, Tretli S, Choueiri TK, Signoretti S, Fall K, Adami HO. Risk of bilateral renal cell cancer. J Clin Oncol. 2009;27:3737–3741. [PubMed] [Google Scholar]

102. Linehan WM. Genetic basis of bilateral renal cancer: implications for evaluation and management. J Clin Oncol. 2009;27:3731–3733. [PMC free article] [PubMed] [Google Scholar]

103. Schwarz A, Vatandaslar S, Merkel S, Haller H. Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol. 2007;2:750–756. [PubMed] [Google Scholar]

104. Fick-Brosnahan GM. Polycystic and acquired cystic kidney disease. In: Greenberg A, editor. Primer on Kidney Diseases. San Francisco: Academic Press; 2001. pp. 303–308. [Google Scholar]

105. Scandling JD. Acquired cystic kidney disease and renal cell cancer after transplantation: time to rethink screening? Clin J Am Soc Nephrol. 2007;2:621–622. [PubMed] [Google Scholar]

106. Chow WH, Gridley G, Fraumeni JF, Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305–1311. [PubMed] [Google Scholar]

107. Parker AS, Cerhan JR, Janney CA, Lynch CF, Cantor KP. Smoking cessation and renal cell carcinoma. Ann Epidemiol. 2003;13:245–251. [PubMed] [Google Scholar]

108. Karami S, Brennan P, Navratilova M, et al. Vitamin d pathway genes, diet, and risk of renal cell carcinoma. Int J Endocrinol. 2010:879362. [PMC free article] [PubMed] [Google Scholar]

109. Bast RC, Jr, Brewer M, Zou C, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 2007;174:91–100. [PubMed] [Google Scholar]

110. Cairns P, Sidransky D. Molecular methods for the diagnosis of cancer. Biochim Biophys Acta. 1999;1423:C11–C18. [PubMed] [Google Scholar]

111. Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer. 2007;7:531–543. [PubMed] [Google Scholar]

112. Battagli C, Uzzo RG, Dulaimi E, et al. Promoter Hypermethylation of Tumor Suppressor Genes in Urine from Kidney Cancer Patients. Cancer Res. 2003;63:8695–8699. [PubMed] [Google Scholar]

113. Hoque MO, Begum S, Topaloglu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res. 2004;64:5511–5517. [PubMed] [Google Scholar]

114. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175:425–431. [PubMed] [Google Scholar]

115. Duffey BG, Choyke PL, Glenn G, et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol. 2004;172:63–65. [PubMed] [Google Scholar]

116. Kontak JA, Campbell SC. Prognostic factors in renal cell carcinoma. Urol Clin North Am. 2003;30:467–480. [PubMed] [Google Scholar]

117. Lam JS, Klatte T, Kim HL, et al. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol. 2008;65:235–262. [PubMed] [Google Scholar]

118. Campbell L, Gumbleton M, Griffiths DF. Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer. 2003;89:1909–1913. [PMC free article] [PubMed] [Google Scholar]

119. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767. [PubMed] [Google Scholar]

120. Béroud C, Fournet J-C, Jeanpierre C, et al. Correlations of allelic imbalance of chromosome 14 with adverse prognostic parameters in 148 renal cell carcinomas. Genes Chromosomes Cancer. 1996;17:215–224. [PubMed] [Google Scholar]

121. Moch H, Presti JC, Jr, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res. 1996;56:27–30. [PubMed] [Google Scholar]

122. Schraml P, Muller D, Bednar R, et al. Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma. J Pathol. 2000;190:457–461. [PubMed] [Google Scholar]